ATE13422T1 - Derivate von 1-aryl-2-aminomethyl-cyclopropancarboxamiden (z), ihre herstellung und ihre verwendung fuer die behandlung von stoerungen des zentralnervensystems. - Google Patents

Derivate von 1-aryl-2-aminomethyl-cyclopropancarboxamiden (z), ihre herstellung und ihre verwendung fuer die behandlung von stoerungen des zentralnervensystems.

Info

Publication number
ATE13422T1
ATE13422T1 AT82401129T AT82401129T ATE13422T1 AT E13422 T1 ATE13422 T1 AT E13422T1 AT 82401129 T AT82401129 T AT 82401129T AT 82401129 T AT82401129 T AT 82401129T AT E13422 T1 ATE13422 T1 AT E13422T1
Authority
AT
Austria
Prior art keywords
aryl
atom
alkyl group
lower alkyl
nervous system
Prior art date
Application number
AT82401129T
Other languages
English (en)
Inventor
Gilbert Mouzin
Henri Cousse
Bernard Bonnaud
Michel Morre
Antoine Stenger
Original Assignee
Fabre Sa Pierre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9259785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE13422(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fabre Sa Pierre filed Critical Fabre Sa Pierre
Application granted granted Critical
Publication of ATE13422T1 publication Critical patent/ATE13422T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT82401129T 1981-06-23 1982-06-21 Derivate von 1-aryl-2-aminomethyl-cyclopropancarboxamiden (z), ihre herstellung und ihre verwendung fuer die behandlung von stoerungen des zentralnervensystems. ATE13422T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8112312A FR2508035A1 (fr) 1981-06-23 1981-06-23 Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
EP82401129A EP0068999B1 (de) 1981-06-23 1982-06-21 Derivate von 1-Aryl-2-aminomethyl-cyclopropan-carboxamiden (Z), ihre Herstellung und ihre Verwendung für die Behandlung von Störungen des Zentralnervensystems

Publications (1)

Publication Number Publication Date
ATE13422T1 true ATE13422T1 (de) 1985-06-15

Family

ID=9259785

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82401129T ATE13422T1 (de) 1981-06-23 1982-06-21 Derivate von 1-aryl-2-aminomethyl-cyclopropancarboxamiden (z), ihre herstellung und ihre verwendung fuer die behandlung von stoerungen des zentralnervensystems.

Country Status (11)

Country Link
US (1) US4478836A (de)
EP (1) EP0068999B1 (de)
JP (1) JPS584752A (de)
AT (1) ATE13422T1 (de)
AU (1) AU550774B2 (de)
CA (1) CA1202639A (de)
DE (1) DE3263734D1 (de)
ES (1) ES512842A0 (de)
FR (1) FR2508035A1 (de)
LU (1) LU90410I2 (de)
ZA (1) ZA824453B (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581060B1 (fr) * 1985-04-25 1988-07-01 Pf Medicament Procede industriel d'obtention du midalcipran
FR2581059B1 (fr) * 1985-04-25 1988-04-22 Pf Medicament Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z)
WO1995022521A1 (fr) * 1994-02-22 1995-08-24 Asahi Kasei Kogyo Kabushiki Kaisha Derive d'aminoalkylcyclopropane
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (de) 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
DE69607904T2 (de) * 1995-08-16 2000-10-05 Eli Lilly And Co., Indianapolis Potenzierung von Serotonin-Wirkstoffresponz
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
EP1434763B1 (de) * 2001-10-12 2018-01-17 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1a antagonisten
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
EP1499309A4 (de) * 2002-04-24 2008-05-28 Cypress Bioscience Inc Prävention und behandlung von funktionellen somatischen erkrankungen, einschliesslich stressbedingten erkrankungen
US7038085B2 (en) * 2002-10-25 2006-05-02 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
FR2851163B1 (fr) 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
ES2310715T3 (es) 2003-02-14 2009-01-16 Pierre Fabre Medicament Uso del enantiomero (1s,2r) del milnacipran para la preparacion de un medicamento.
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法
MXPA06001738A (es) * 2003-08-15 2006-05-12 Lundbeck & Co As H Derivados de ciclopropilo como antagonistas del receptor nk3.
CN1867549B (zh) * 2003-08-15 2011-07-06 H·隆德贝克有限公司 作为nk3受体拮抗剂的环丙基衍生物
DK1691811T3 (da) 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
EP1737473A4 (de) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Lithium-kombinationen und relevante verwendungen
US9597314B2 (en) 2005-03-22 2017-03-21 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
TW200719886A (en) * 2005-04-22 2007-06-01 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
JP2008538572A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
MX2007013021A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
CA2611724C (en) * 2005-06-10 2014-07-29 Pierre Fabre Medicament S.A. Stabilized milnacipran formulation
JP2009500043A (ja) * 2005-07-08 2009-01-08 ブレインセルス，インコーポレイティド 神経新生を調節する薬剤及び条件を同定する方法
PL1910346T3 (pl) 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
US20090203750A1 (en) * 2005-08-24 2009-08-13 Alan Kozikowski 5-HT2C Receptor Agonists as Anorectic Agents
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
JPWO2007086493A1 (ja) * 2006-01-27 2009-06-25 旭化成ファーマ株式会社 経鼻投与用薬剤
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2644662A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
WO2008086483A2 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
US20100145099A1 (en) * 2007-02-28 2010-06-10 Ranbaxy Laboratories Limited Novel polymorphic forms of milnacipran hydrochloride
WO2009023820A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
US20090069431A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched milnacipran
EP2288345B1 (de) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psychopharmazeutika
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010036773A1 (en) * 2008-09-24 2010-04-01 Concert Pharmaceuticals, Inc. Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives
FR2941454B1 (fr) 2009-01-29 2011-04-01 Pf Medicament Proced de synthese du (1s,2r)-milnacipran
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20100274050A1 (en) * 2009-04-23 2010-10-28 Glenmark Generics Limited Solid milnacipran and process for the preparation of the same
WO2010129689A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Limited Milnacipran formulations
WO2011016057A2 (en) 2009-08-05 2011-02-10 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
US8865937B2 (en) * 2009-11-06 2014-10-21 Mahendra G. Dedhiya Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
WO2011092065A1 (en) 2010-01-29 2011-08-04 Nicox S.A. Nitric oxide releasing compounds for the treatment of neurophatic pain
PL2587919T3 (pl) 2010-07-01 2018-05-30 Azevan Pharmaceuticals, Inc. Sposoby leczenia zespołu stresu pourazowego
WO2012028922A2 (en) 2010-08-30 2012-03-08 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
WO2012059933A1 (en) 2010-11-03 2012-05-10 Arch Pharmalabs Limited A new process for preparing optically pure milnacipran and its pharmaceutically acceptable salts.
WO2012145234A2 (en) * 2011-04-21 2012-10-26 Emory University Cyclopropyl derivatives and methods of use
WO2014009767A1 (en) 2012-07-07 2014-01-16 Micro Labs Limited An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts
WO2014203277A2 (en) * 2013-06-19 2014-12-24 Msn Laboratories Private Limited Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride
IN2013MU03122A (de) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
PL3122743T3 (pl) 2014-03-28 2023-05-02 Azevan Pharmaceuticals, Inc. Kompozycje i sposoby leczenia chorób neurodegeneracyjnych
MX2020002762A (es) 2017-09-15 2020-09-17 Azevan Pharmaceuticals Inc Composiciones y métodos para tratar una lesión cerebral.
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA570688A (en) * 1959-02-17 E. Speeter Merrill Antispasmodic substituted amines
CA619080A (en) * 1961-04-25 The Upjohn Company N-SUBSTITUTED-.alpha.-(TERTIARY-AMINOALKYL)-.alpha.-PHENYLACETAMIDES
GB1415541A (en) * 1972-11-30 1975-11-26 Hexachimie 1-amino-methyl-2,2-diarylcyclopropanecarboxamide

Also Published As

Publication number Publication date
ZA824453B (en) 1983-04-27
JPS6323186B2 (de) 1988-05-16
AU550774B2 (en) 1986-04-10
JPS584752A (ja) 1983-01-11
US4478836A (en) 1984-10-23
EP0068999B1 (de) 1985-05-22
ES8303293A1 (es) 1983-03-01
EP0068999A1 (de) 1983-01-05
CA1202639A (fr) 1986-04-01
ES512842A0 (es) 1983-03-01
FR2508035A1 (fr) 1982-12-24
FR2508035B1 (de) 1984-06-29
LU90410I2 (fr) 1999-08-31
DE3263734D1 (en) 1985-06-27
AU8508682A (en) 1983-01-06

Similar Documents

Publication Publication Date Title
ATE13422T1 (de) Derivate von 1-aryl-2-aminomethyl-cyclopropancarboxamiden (z), ihre herstellung und ihre verwendung fuer die behandlung von stoerungen des zentralnervensystems.
DE3762618D1 (de) Amidderivate.
FI935529A0 (fi) Aminometylensubstituerade icke-aromatiska heterocykliska foereningar
NO960380D0 (no) Middel til behandling av neurosykdommer
ATE28565T1 (de) Spiro(4.(3+n))-2-aza-alkan-3-carbonsaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung.
DE69113155D1 (de) 17-beta-substituierte-4-aza-5-alpha-androstan-3-one-derivate und verfahren zu ihrer herstellung.
DE69418789D1 (de) 2-(Piperidin-4-yl, Pyridin-4-yl und Tetrahydropyridin-4-yl)-benzofuran-7-carbamat Derivate, ihre Herstellung und Verwendung als Acetylcholinesterase Inhibitoren
FR2800735B1 (fr) Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
DK519985D0 (da) Quinoloncarboxylsyrederivater, fremgangsmaade til fremstilling deraf og antibakterielt middel indeholdende saadanne derivater
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
EE200000059A (et) Tetrahüdro-gamma-karboliinid
ATE121385T1 (de) Harnstoffderivate, ihre herstellung und ihre verwendung bei der therapie.
ES2094840T3 (es) 1-(pirido(3,4-b)-1,4-oxazinil-4-il)-1h-indoles, compuestos intermedios y un procedimiento para su preparacion, y su uso como medicamentos.
ES544417A0 (es) Procedimiento para preparar 8-alquiltio-2-piperazino-pirimido(5,4-d)pirimidinas.
ATE226585T1 (de) Thiazolobenzoheterocyclen, ihre herstellung und diese enthaltende phatrmazeutische zubereitungen
DE69110219D1 (de) 3-(1H-Indazol-3-yl)-4-pyridiname, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
ES518186A0 (es) Procedimiento para preparar alquenamidas y fenilalquenamidas n,n-disubstituidas.
FI834798A (fi) Foerfarande foer framstaellning av 1-(aminoalkoxifenyl)-1-fenyl-propanoler.
ES2085540T3 (es) 2-(3-fenilpropil)hidrazinas, productos intermedios en y un procedimiento para la preparacion de las mismas, y su uso como medicamentos.
IT1210914B (it) Eterociclilfenilsolfonil e fosfonilamidine sostituite, procedimento per la loro preparazione e loro uso farmaceutico.
TH11174EX (th) อนุพันธ์ของพิเพอดิลอกซิ-ไอซอกซาโซล,การเตรียมสารเหล่านั้นและการใช้ในการรักษา